Lisata Therapeutics Acquires Marea, Secures $225M in Private Funding

Key Facts

1Lisata Therapeutics acquired Marea Therapeutics to bolster its cardioendocrine pipeline strategy.

2The company secured $225 million in private financing to support Phase 2 clinical trials.

In a move reflecting the accelerating pace of consolidation within the biotech sector, Lisata Therapeutics has announced the acquisition of Marea Therapeutics. This strategic transaction is designed to bolster the company's cardioendocrine pipeline strategy. According to reports, the acquisition aligns with broader efforts to expand its therapeutic reach through targeted M&A.

Alongside the acquisition, the company secured $225 million in private financing specifically to support its upcoming Phase 2 clinical trials. This substantial capital injection provides the necessary liquidity to advance its drug development pipeline. Such funding rounds are critical for clinical-stage companies aiming to reach key developmental milestones without immediate public market dilution.

LSTA shares stood at $1.47 at close on September 16, 2026, having traded within a daily range of $1.47 to $1.57 per market data. Investors will be watching for updates regarding the initiation of Phase 2 trials, especially as broader market sentiment remains influenced by recent US inflation data, which showed a steady 3.4% annual rate as of September 11, 2026.